Navigation Links
Drug Development in Arizona Gets Boost Following ASU-Quintiles Agreement
Date:9/17/2010

PHOENIX, Sept. 17 /PRNewswire/ -- Arizona's contribution to the accelerated development of new, safe and effective medicines to help treat suffering patients in the US and around the world, will become greater following the signing of new deal between Arizona State University and Quintiles (www.quintiles.com), a global integrated biopharmaceutical services company which is a leader in managing clinical research.

The Center for Healthcare Innovation & Clinical Trials (https://nursingandhealth.asu.edu/clinical-trials).at ASU – part of the College of Nursing & Health Innovation – is only the fifth organization in the world to become a global prime site partner for Quintiles.

Through Quintiles the Center will receive access to many more clinical research initiatives. In return, the Center will deploy its unique community-based model to recruit more physicians and nurse practitioners who can identify patients who are willing and eligible to participate in the research.

Access to patients to participate in clinical trials is one of the major barriers to bringing much needed safe and effective drugs to market faster and with less cost.

Linda Mottle, Director of the Center for Healthcare Innovation & Clinical Trials at ASU, noted that the clinical research market in Arizona lags other states with comparable population sizes and explained: "We believe our community-based model can substantially increase the clinical research market in Arizona."

Adam Chasse, Senior Director for Patient Access at Quintiles, added: "Access to patients is one of the toughest hurdles in working with our biopharmaceutical customers to accelerate outcomes and get better value from the drug development process.  This agreement with ASU will help our customers to meet study milestones more effectively by providing access to large gr
'/>"/>

SOURCE Arizona State University College of Nursing & Health Innovation
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. DNASequencing.com and a Portfolio of 318 Genetic Domain Names to be Auctioned Off at Epik.com Domain Development Conference
2. Oxford Finance Corporation Hires Dr. Killu Sanborn to Support Life Science Business Development in Western North America
3. Jennerex and Transgene Enter Into an Exclusive Partnership for the Development and Commercialization of JX-594 for the Treatment of Cancers
4. Zero Discharge Sweet Sorghum Ethanol Process Development
5. NASA funds development of nanoscale materials for high energy density lithium-ion batteries
6. PharmaNet Development Group Appoints Anthony Maida, Vice President, Clinical Research
7. Cord Blood America CEO Updates Investors on Financial Developments and Stem Cell News in Interview
8. Torbjorn Bjerke Appointed as new CEO for Karolinska Development
9. Silence Therapeutics Partner Quark Signs Exclusive Option Agreement With Novartis for Development and Commercialisation of QPI-1002
10. Clean Power Development, LLC Urges Sustainable, Community-Centric Approach to Biomass Energy
11. Elusys Awarded Additional $40.6 Million Under Existing U.S. Government Contract to Fund Advanced Development of Anthim, a New Treatment for Anthrax
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... transplant rejection occurs when the transplant recipient,s immune system ... it. It was previously thought that T cells, the ... by molecules known as chemokines in order to migrate ... Journal of Clinical Investigation , Fadi Lakkis and ... demonstrate that chemokine stimulation of T cells is not ...
(Date:5/17/2013)... provider of scientific, technical and medical information products and ... in Reproductive BioMedicine Online on ... abnormal chromosomal composition can be identified by the rate ... the risk of genetic abnormality without a biopsy. In ... retrospective study, using their predictive model to assess the ...
(Date:5/17/2013)... 2013 •    First of its kind research ... ,     New facility will help solve crop stresses ... Syngenta unveiled its new crop research facility during ... Innovation Center. The first of its kind, $72 million ... agricultural climate and precisely measure plant inputs – the ...
(Date:5/17/2013)... ALTO, Calif. , May 17, 2013 /PRNewswire/ ... it has achieved 50% enrollment of the total ... to evaluate the safety and preliminary efficacy of ... Cells) therapy for Knee Osteoarthritis (KOA). To date ... (SAE) reported. The Phase I open ...
Breaking Biology Technology:Breakthrough for IVF? 2Breakthrough for IVF? 3Syngenta Opens Unique $72 Million Advanced Crop Lab 2Syngenta Opens Unique $72 Million Advanced Crop Lab 3Cellular Biomedicine Group Achieves 50% Enrollment Milestone in Phase I Clinical Trial for Knee Osteoarthritis 2
... Calif., March 10 MannKind,Corporation (Nasdaq: MNKD ... recent market events:, MannKind is absolutely committed ... Technosphere(R) Insulin. We use our small,patient-friendly Medtone(R) inhaler ... a way that much more closely matches the ...
... Judith K. Gwathmey VMD, Ph.D., FACC,FAHA has served ... Inc. for twelve years. Gwathmey, Inc. is an ... evaluation,of lead compounds prior to their conversion into ... a campaign with other members of the,quiet rural ...
... Anavex Life,Sciences Corp. ("ANAVEX") (OTCBB: AVXL) today announced ... delay the growth of cancerous,tumors in patient-derived xenografts ... developed in ANAVEX labs using a sample,taken from ... cell sarcoma,is a rare type of melanoma (skin ...
Cached Biology Technology:MannKind Corporation Response to Recent Market Events 2MannKind Corporation Response to Recent Market Events 3MannKind Corporation Response to Recent Market Events 4MannKind Corporation Response to Recent Market Events 5MannKind Corporation Response to Recent Market Events 6Anavex 7-1037 reduces rate of cancer tumor growth 69% in pre-clinical studies, compared to currently marketed drug Dacarbazine showing no measurable activity 2Anavex 7-1037 reduces rate of cancer tumor growth 69% in pre-clinical studies, compared to currently marketed drug Dacarbazine showing no measurable activity 3Anavex 7-1037 reduces rate of cancer tumor growth 69% in pre-clinical studies, compared to currently marketed drug Dacarbazine showing no measurable activity 4Anavex 7-1037 reduces rate of cancer tumor growth 69% in pre-clinical studies, compared to currently marketed drug Dacarbazine showing no measurable activity 5Anavex 7-1037 reduces rate of cancer tumor growth 69% in pre-clinical studies, compared to currently marketed drug Dacarbazine showing no measurable activity 6
(Date:5/16/2013)... Fish fossils that are about 23 million years ... of the gobioid order, one of the most ... Researchers led by paleontologist Professor Bettina Reichenbacher from ... Department of Earth and Environmental Sciences at Ludwig-Maximilians-Universitaet ... comprehensive analysis of fish fossils which they assign ...
(Date:5/16/2013)... in Cameroon and the manager of San Diego Zoo ... prestigious Whitley award. The Whitley award is an ... because it celebrates the extraordinary achievements of some of ... Abwe was selected for the award due to his ... and its wildlife inhabitants., HRH The Princess Royal, the ...
(Date:5/15/2013)... moderating gout risk, new research reveals that vitamin C, ... (urate) levels to a clinically significant degree in patients ... combination with allopurinol, appears to have a weak effect ... to the results published in the American College of ... , Gout is an inflammatory arthritis that causes excruciating ...
Breaking Biology News(10 mins):Paleontology: The eloquence of the otoliths 2Paleontology: The eloquence of the otoliths 3Cameroon researcher wins prestigious 'Green Oscar' 2Cameroon researcher wins prestigious 'Green Oscar' 3Vitamin C does not lower uric acid levels in gout patients 2
... Richard C. Willson has been named a 2010 Fellow ... (AAAS), which is the world,s largest general scientific society ... Willson is a professor of chemical and biomolecular engineering ... the AAAS for his "distinguished contributions to biomolecular recognition ...
... Conservation paleobiologists--scientists who use the fossil record to ... species to changes in their environment--are putting the ... the research in this emerging field provides examples ... environmental impacts, predict which species will be most ...
... Institute who have been studying prostate cancer cells for decades ... cancer progression. "This is the first demonstration of a ... a tumor to produce," said senior author Sal Pizzo, M.D., ... willing to bet there is also a connection in cancerous ...
Cached Biology News:University of Houston professor named 2010 AAAS Fellow 2Putting the dead to work 2Putting the dead to work 3Researchers learn why PSA levels reflect prostate cancer progression 2Researchers learn why PSA levels reflect prostate cancer progression 3
Rabbit Anti-conjugated Agmatine Polyclonal Antibody...
ABCA1 Immunogen: Mouse ABCA1-expressing HeLa stable transfectants. Storage: -20 C, Avoid Freeze/Thaw Cycles...
... Rabbit polyclonal to ADAMTS16 ( ... Antigen: Synthetic ... of human ADAMTS-16. Note: the amino ... Entrez GeneID: 170690 ...
Goat polyclonal to SART3 ( Abpromise for all tested applications). Antigen: Synthetic peptide: MSNADFAKLFLRK, corresponding to C terminal amino acids 951-963 of Human SART3 Entrez Gene ID: 9...
Biology Products: